Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma

Liver International

Volumn 31, Issue 6, 2011, Pages 792-801

  Decaens, Thomas ^a,b,c   Roudot Thoraval, Françoise ^a,b   Badran, Hanaa ^a   Wolf, Philippe ^d   Durand, François ^e   Adam, Rene ^f   Boillot, Olivier ^g   Vanlemmens, Claire ^h   Gugenheim, Jean ⁱ   Dharancy, Sébastien ^j   Bernard, Pierre Henri ^k   Boudjema, Karim ^l   Calmus, Yvon ^m   Hardwigsen, Jean ⁿ   Ducerf, Christian ^o   Pageaux, Georges Philippe ^p   Hilleret, Marie Noelle ^q   Chazouillères, Olivier ^r   Cherqui, Daniel ^a,b   Mallat, Ariane ^a,b,c   Duvoux, Christophe ^a,b   more..

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c INSERM U955   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e BEAUJON HOSPITAL   (France)

^f HÔPITAL PAUL BROUSSE   (France)

^g Hospices Civiles de Lyon   (France)

^h UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k HÔPITAL SAINT ANDRÉ   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m Institut Cochin   (France)

ⁿ HÔPITAL DE LA CONCEPTION   (France)

^o CROIX ROUSSE HOSPITAL   (France)

^p HÔPITAL SAINT ELOI   (France)

^q GRENOBLE UNIVERSITY HOSPITAL   (France)

^r HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

Hepatocellular carcinoma; Liver transplantation; Milan criteria; Prognostic score

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BILIRUBIN; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

EID: 79958060925     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02425.x     Document Type: Article

References (42)

1. Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet 1999; 354: 1636-9.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
3. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311-22.
4. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-83.
5. Figueras J, Jaurrieta E, Valls C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-9.
6. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
7. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12: 1761-9.
8. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl 2003; 9: 693-6.
9. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-25.
10. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-6.
11. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25-30.
12. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228: 479-90.
13. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
14. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-40.
15. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002; 6: 224-32; discussion 32.
16. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-9.
17. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191: 389-94.
18. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88: 538-43.
19. Han K, Tzimas GN, Barkun JS, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45.
20. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503.
21. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-8.
22. Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 1195-202.
23. De Carlis L, Giacomoni A, Pirotta V, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 2003; 196: 887-97.
24. Zhang M, Li B, Yan LN, et al. Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol 2008; 14: 1280-5.
25. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003; 9: 664-71.
26. Schwartz M, Dvorchik I, Roayaie S, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008; 49: 581-8.
27. Mas VR, Maluf DG, Archer KJ, et al. Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med 2006; 12: 97-104.
28. Mas VR, Fisher RA, Archer KJ, et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results. Transplantation 2007; 83: 973-81.
29. Karnofsky DA. Palliation and life prolongation with anticancer drugs. CA Cancer J Clin 1966; 16: 117-9.
30. Bosman FT, Carneiro F, Hruban RH, Theise ND (ed.). WHO Classification of Tumours of the Digestive System, 4th edn. Geneva: WHO Press; 2010.
31. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
32. Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop. Gynecol Oncol 2007; 107: 173-6.
33. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-24.
34. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
35. Duvoux C, Decaens T, Roudot-Thoraval F, et al. Prediction of survival after liver transplantation (LT) for hepatocellular carcinoma (HCC) using the TNM staging classification modified for LT/validation in a French cohort. J Hepatol 2003; 38: A39.
36. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the international tumor registry. Liver Transpl 2002; 8: 736-48.
37. Sotiropoulos GC, Molmenti EP, Losch C, et al. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1198 cases. Eur J Med Res 2007; 12: 527-34.
38. Smith EH. The hazards of fine-needle aspiration biopsy. Ultrasound Med Biol 1984; 10: 629-34.
39. Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 2000; 6: 67-72.
40. Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 2007; 245: 435-42.
41. Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14: 272-8.
42. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684-92.